Evaluation of Efficacy and Safety of Milsaperidone As Adjunctive Therapy in Patients with Major Depressive Disorder
Phase 3
Not yet recruiting
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06830044
Food Effect Study of VHX-896 in Healthy Volunteers
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT06803290
- Locations
- 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath